Headway welcomes findings of trifluoperazine study
Headway has given a cautious welcome to the findings of a new study which found the antipsychotic drug trifluoperazine (TFP) to be successful in reducing swelling following brain injuries.
The new treatment, developed by scientists at Aston University in partnership with international academic institutions, works by counteracting the cells’ normal reaction to a loss of oxygen in the brain when trauma occurs.
Peter McCabe, Chief Executive of Headway – the brain injury association, said: “We welcome any research that could lead to an improvement of the treatment of brain injuries.
“Every three minutes someone in the UK is admitted to hospital with a head injury, the consequences of which can be devastating and last a lifetime, so it’s encouraging to hear about the findings of this study.
“We believe that further research is required to better understand the impact of this drug. Indeed, the study has identified potential adverse side effects, including links to depression, and this is something that would need to be explored and carefully monitored.
“We look forward to seeing how this research continues to progress.”
For more information about the study please contact a committee member.